Arizona State Office of Rural Health (SORH) Webinar Series

The SORH provides technical assistance to rural stakeholders to disseminate research findings, policy updates, best-practices and other rural health issues to statewide rural partners and stakeholders.
Arizona State Office of Rural Health

This webinar is made possible with the support of our partners:
Webinar Tips & Notes

- Audience is muted during the presentation.
- Enter your questions into the chat box.
- Please fill out the post-webinar survey
- Webinar is being recorded
- Recording will be posted on the AzCRH www.crh.arizona.edu/ and SWTRC www.southwesttrc.org/
Today’s presentation:

Controlled Substances Prescription Monitoring Program

CSPMP, Statutes, COVID-19, and Resources for You

Lynn Curtis, Marketing Specialist
Arizona Board of Pharmacy
Today’s Presentation

- The PMP
- Updates to the Statutes
- COVID-19 Updates
- Additional Tools/Resources
# What is the PMP?

## Test Patent

**Name**: Test Patient  
**DOB**: 01/01/1980  
**ID**: 1  
**Gender**: Female  
**Address**: 286 Folsom Dr, Phoenix, AZ 85020

**Test Patient**:  
**DOB**: 01/01/1980  
**ID**: 2  
**Gender**: Unknown  
**Address**: 10461 Lrinkton Rd, Ste 281, Louisville, KY 40223

## Test Criteria

**First Name**: Test  
**Last Name**: Patient  
**DOB**: 01/01/1980

<table>
<thead>
<tr>
<th>Summary</th>
</tr>
</thead>
</table>
| Total Prescriptions   | 16  
| Total Private Pay      | 14  
| Total Prescribers      | 7   
| Total Pharmacies       | 6   

### Summary

| Opioids (excluding buprenorphine) | Buprenorphine  
|----------------------------------|--------------  
| Current Qty                      | Current Qty  
| MME/day                          | mg/day       
| 30 Day Avg MME/day               | 30 Day Avg mg/day  

### Prescriptions

<table>
<thead>
<tr>
<th>Filled Date</th>
<th>ID</th>
<th>Written Date</th>
<th>Drug</th>
<th>QTY</th>
<th>Days</th>
<th>Prescriber</th>
<th>Rx #</th>
<th>Pharmacy*</th>
<th>Refills</th>
<th>Daily Dose</th>
<th>Pyrim Type</th>
<th>PMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/08/2018</td>
<td>1</td>
<td>03/08/2018</td>
<td>OCTYCONT 30 MG TABLET</td>
<td>90.0</td>
<td>0</td>
<td>Co Tom</td>
<td>115810</td>
<td>Dowel (AZ)</td>
<td>0</td>
<td>0</td>
<td>AZ</td>
<td></td>
</tr>
</tbody>
</table>
# Patient Utilization Report

**Report Prepared:** 05/14/2019  
**Date Range:** 05/14/2014 – 05/14/2019

**Test Patient**

<table>
<thead>
<tr>
<th>Name</th>
<th>DOB</th>
<th>ID</th>
<th>Gender</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Patient</td>
<td>01/01/1900</td>
<td>1</td>
<td>female</td>
<td>555 Fake Dr. Wichita KS 6</td>
</tr>
<tr>
<td>TEST PATIENT</td>
<td>01/01/1900</td>
<td>3</td>
<td></td>
<td>555 FAKE DR WITCHITA KS 67203</td>
</tr>
<tr>
<td>Test Patient</td>
<td>01/01/1900</td>
<td>2</td>
<td>unknown</td>
<td>10401 LINN STATION RD STE 201 LOUISVILLE KY 40223</td>
</tr>
</tbody>
</table>

**Report Criteria**  
**First Name:** test, **Last Name:** patient, **DOB:** 01/01/1900

**Summary**

<table>
<thead>
<tr>
<th>Summary</th>
<th>Opioids* (excluding buprenorphine)</th>
<th>Buprenorphine*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Prescriptions</td>
<td>15 Current Qty 0.0</td>
<td>Current Qty 0.0</td>
</tr>
<tr>
<td>Total Private Pay</td>
<td>14 Current MME/day 0.0</td>
<td>Current mg/day 0.0</td>
</tr>
<tr>
<td>Total Prescribers</td>
<td>7 30 Day Avg MME/day 0.0</td>
<td>30 Day Avg mg/day 0.0</td>
</tr>
</tbody>
</table>
## Prescriptions

<table>
<thead>
<tr>
<th>Filled</th>
<th>ID</th>
<th>Written</th>
<th>Drug</th>
<th>QTY</th>
<th>Days</th>
<th>Prescriber</th>
<th>Rx #</th>
<th>Pharmacy*</th>
<th>Refills</th>
<th>Daily Dose</th>
<th>Pymt Type</th>
<th>PMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/02/18</td>
<td>1</td>
<td>03/02/18</td>
<td>OXYCONTIN 20 MG TABLET</td>
<td>60.0</td>
<td>0</td>
<td>Ca Tes</td>
<td>7789456</td>
<td>Dave' (0000)</td>
<td>0</td>
<td>7.5 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>10/05/17</td>
<td>2</td>
<td>10/05/17</td>
<td>OXYCODONE-ACETAMINOPHEN 5-325</td>
<td>1.0</td>
<td>1</td>
<td>Ap Pre</td>
<td>10052017</td>
<td>Appri (0000)</td>
<td>0</td>
<td>10.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>10/05/17</td>
<td>2</td>
<td>10/05/17</td>
<td>HYDROCODON-ACETAMINOPHEN 10-325</td>
<td>1.0</td>
<td>1</td>
<td>Ap Pre</td>
<td>20171005</td>
<td>Appri (0000)</td>
<td>0</td>
<td>10.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>01/10/17</td>
<td>3</td>
<td>01/10/17</td>
<td>OXYCONTIN 80 MG TABLET</td>
<td>60.0</td>
<td>30</td>
<td>CA TES</td>
<td>TP000005</td>
<td>Carol (2222)</td>
<td>0</td>
<td>409.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>01/04/17</td>
<td>3</td>
<td>01/04/17</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>30</td>
<td>AL TES</td>
<td>TP000000</td>
<td>Alice (4567)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>01/03/17</td>
<td>3</td>
<td>01/03/17</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>30</td>
<td>DA TES</td>
<td>TP000008</td>
<td>Dave' (0000)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>12/14/16</td>
<td>3</td>
<td>12/14/16</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>60</td>
<td>EV TES</td>
<td>TP000011</td>
<td>Dave' (0000)</td>
<td>0</td>
<td>40.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>12/14/16</td>
<td>3</td>
<td>12/14/16</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>30</td>
<td>DA TES</td>
<td>TP000009</td>
<td>Dave' (0000)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>12/11/16</td>
<td>3</td>
<td>12/11/16</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>25</td>
<td>BO TES</td>
<td>TP000002</td>
<td>Bob's (1111)</td>
<td>0</td>
<td>96.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
<tr>
<td>12/07/16</td>
<td>3</td>
<td>12/07/16</td>
<td>OXYCODONE HCL 20 MG TABLET</td>
<td>60.0</td>
<td>30</td>
<td>AL TES</td>
<td>TP000001</td>
<td>Alice (4567)</td>
<td>0</td>
<td>80.0 MME</td>
<td>Private Pay</td>
<td>AZ</td>
</tr>
</tbody>
</table>
# Patient Utilization Report

## Prescribers

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescriber, Appriss</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testprescriber, Carol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TESTPREScriber, EVE</td>
<td>10110 TEST ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67204</td>
<td></td>
</tr>
<tr>
<td>TESTPREScriber, ALICE</td>
<td>1111 FAKE ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67203</td>
<td></td>
</tr>
<tr>
<td>TESTPREScriber, CAROL</td>
<td>2510 HIGH ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67203</td>
<td></td>
</tr>
</tbody>
</table>

## Dispensers

<table>
<thead>
<tr>
<th>Pharmacy</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dave's PHARMACY CHAIN (0000)</td>
<td>7th TEST ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67212</td>
<td>3165551111</td>
</tr>
<tr>
<td>Dave's Pharmacy Chain (0000)</td>
<td>7TH TEST ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67212</td>
<td></td>
</tr>
<tr>
<td>Carol's PHARMACY CHAIN (2222)</td>
<td>2nd NOWHERE ST</td>
<td>WICHITA</td>
<td>KS</td>
<td>67206</td>
<td>3365550000</td>
</tr>
<tr>
<td>Bob's PHARMACY (1111)</td>
<td>1234 NOT-A-REAL-PLACE DR</td>
<td>WICHITA</td>
<td>KS</td>
<td>67202</td>
<td>31600000000</td>
</tr>
<tr>
<td>Appriss Pharmacy (0000)</td>
<td>10401 LINN STATION RD</td>
<td>LOUISVILLE</td>
<td>KY</td>
<td>40223</td>
<td>8662777477</td>
</tr>
<tr>
<td>Alice's PHARMACY (4567)</td>
<td></td>
<td></td>
<td></td>
<td>67202</td>
<td></td>
</tr>
</tbody>
</table>
Arizona Opioid Epidemic Act
It’s the Law - Registration

A prescriber who has:

- Valid license from a state licensing board
- Valid DEA registration number(s)

A pharmacist who has:

- Valid license from State Board of Pharmacy
- Employed at facility with valid DEA #

A.R.S. § 36-2606
It's the Law - Who has access the PMP

- Prescribers
- Pharmacists
- Delegates
- Licensing boards
- Medical Examiners

- Law enforcement/criminal justice agencies
  - Affidavit
- Medicaid fraud investigators
- Attorneys
  - Court orders
- Individual patients
Prescribers – Patient Report

- Before prescribing an opioid or benzodiazepine
- Include preceding 12 months
- Initial course of treatment
- Every 3 mo. during ongoing treatment
Exemptions to Reviewing the Report

- Cancer diagnosis
- Traumatic injury (fractures, amputations, burns)
- Hospice, palliative, end of life care
- Skilled nursing facility
- Medication-Assisted Treatment (MAT)
Pharmacists – Patient Report

- Before dispensing a C2 Controlled Substance
- Past 12 month report (Default)
- For each new course of treatment
Appropriate Uses

- To provide medical or pharmaceutical care to a patient OR to evaluate a patient

- Part of an open investigation
  - Law Enforcement
  - Medicaid Investigator
  - Licensing boards
Advantages to using the PMP

- Assists in prescribing/dispensing appropriately
  - Best Practice/Standard of Care

- Identify, deter, and prevent abuse and diversion of prescription CS drugs

- Safeguard your DEA number
May no longer dispense C2 opioids
- MAT dispensations are exempt

Must report daily
- All controlled substances dispensed
- Including “zero” reports
- MAT dispensations are exempt
COVID-19 Information

- Board of Pharmacy
- Medical Professionals
  - Visit your licensing board website often!

pharmacy.az.gov
Executive Order – Board of Pharmacy

March 11, 2020
  ❖ Public Health State of Emergency Declared

April 2, 2020
  ❖ Executive Order Issued by Governor
Board of Pharmacy FAQs

- If Pharmacies need to close
  - To-Do list
    - Notify Board of Pharmacy
    - Communicate to patients/prescribers
      - Include expected reopen date
      - How to transfer/fill at other pharmacies

- Changing operation hours allowed
Board of Pharmacy FAQs

- Receiving Prescriptions
  - EPCS is still available (C2 Opioids)
    - Maybe handwritten
  - Phone, Fax, scan or photo (C2 Medications)
    - Original is kept by prescriber
Consultations with Pharmacist (New Prescriptions)

- Telephone, drive thru, other technological means
- Signature of patient not required to document consultation with pharmacist

Working By Remote Access

- Both pharmacists and technicians may work remotely
- See FAQs for requirements
Dispensing quantity greater than prescribed

- Maintenance medications
- Pharmacists are allowed if refills still exist
  - Must exercise professional judgment
  - Must follow prescribers instructions
  - Recommended to reach out to prescriber
Board of Pharmacy FAQs

- Licensure
  - Technician trainee – expiring licenses will be extended up to 6 months after the health emergency has been lifted
    - Pharmacists licenses are renewed in October
  - Immunizing Pharmacists - expiring CPR certifications will be extended up to 6 months after the health emergency has been lifted
Integration – PMP Direct to your EHR/PS

- PMP Button in EHR/PS
  - Saves time
  - Keeps focus on patient

- Aware system still available

I heard it was difficult to use?!?!
Integration Webpage

- General Info
- FAQs
- Useful Links

https://pharmacypmp.az.gov/integration/statewide-integration-resources
Delegates
Ultimate Goal: Well-being of patients
Resources – PMP Website

- Latest announcements/updates
- Training material/FAQs
- Important links and forms
- Contact Information

https://pharmacypmp.az.gov/
Resources – Training Videos

- Registration
- Request a patient report
- Understand a patient report

https://pharmacypmp.az.gov/pmp-training
Questions
Questions and Discussion
Please type your questions and comments into the Zoom Webinar Platform Chat box.

Controlled Substances Prescription Monitoring Program

CSPMP, Statutes, COVID-19, and Resources for You
Thank you!

Your opinion is valuable to us. Please participate in this brief survey:

https://uarizona.co1.qualtrics.com/jfe/form/SV_2OtV69JRcqnBxX

Find this and our previous webinars at:
http://www.crh.arizona.edu/programs/sorh/webinars

This webinar is made possible through funding provided by Health Resources and Services Administration, Office for the Advancement of Telehealth (G22RH24746), Arizona State Office of Rural Health is funded granted through a grant from US Department of Health and Human Services. Grant number H95RH00102-25-00

This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, DHHS or the U.S. Government.
Controlled Substances Prescription Monitoring Program

Thanks for Attending!